TheraRadar
Clinical-Stage Companies / GC Cell Corporation

GC Cell Corporation

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 3/7/2025

11
Total Trials
3
Phase 3
5
Phase 2
2
Recruiting
97
Score

Pipeline by Phase

Phase 3
3
Phase 2
5
Phase 1
4

Therapeutic Focus

Hepatocellular Carcinoma Glioblastoma Lymphoma, T-Cell Breast Cancer Gastric Cancer

Clinical Trials (11)

NCT04969731 Phase 3 RECRUITING

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Started: 9/7/2021

NCT00807027 Phase 3 COMPLETED

Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea

Started: 12/5/2008

NCT00699816 Phase 3 COMPLETED

Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients

Started: 7/1/2008

NCT00965718 Phase 2 COMPLETED

Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer

Started: 9/1/2009

NCT01897610 Phase 2 COMPLETED

Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC

Started: 12/1/2013

NCT02856815 Phase 2 COMPLETED

Safety and Efficacy of "Immuncell-LC" in TACE Therapy

Started: 5/28/2018

NCT02854839 Phase 2 COMPLETED

A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma

Started: 11/28/2016

NCT06699771 Phase 1 RECRUITING

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Started: 3/7/2025

NCT06341647 Phase 1 WITHDRAWN

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Started: 10/31/2024

NCT03983967 Phase 1 COMPLETED

Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation

Started: 1/24/2019

NCT05238532 Phase 1 WITHDRAWN

Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS

Started: 1/26/2022

Drug Candidates

Activated T lymphocyte(Immuncell-LC) GCC2005 Cyclophosphamide Fludarabine AB-201 Activated T lymphocyte Immuncell-LC Gemcitabine MG4101
Activity Status: Slowing
Last Trial Started: 3/7/2025
Last Trial Ended: 9/22/2022
Trials (12 months): 0
Completed Trials: 7
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.